MODIFICATION
A -- Advanced Development of More Effective/Universal Influenza Vaccines - Solicitation 1
- Notice Date
- 3/16/2015
- Notice Type
- Modification/Amendment
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Office of the Secretary, Acquisitions Management, Contracts, & Grants (AMCG), Office of the Assistant Secretary for Preparedness & Response (ASPR), Department of Health and Human Services, 330 Independence Ave. SW, G640, Washington, District of Columbia, 20201, United States
- ZIP Code
- 20201
- Solicitation Number
- BARDA_Universal_Influenza_Synopsis
- Response Due
- 4/30/2015 5:00:00 PM
- Point of Contact
- Matthew McCord, , Kevin Nilles,
- E-Mail Address
-
matthew.mccord@hhs.gov, kevin.nilles@hhs.gov
(matthew.mccord@hhs.gov, kevin.nilles@hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Request for Proposals No. 15-100-SOL-00014 This is Request for Proposals No. 15-100-SOL-00014. Prevention of disease caused by seasonal and novel influenza strains of pandemic potential continues to be a public health challenge. Vaccination is the primary medical intervention for prevention of infection with these viruses. Seasonal influenza vaccines, which are produced and administered annually, are only 30% to 70% effective. Excess morbidity and mortality caused by seasonal influenza virus disease can be devastating in terms of years of life lost and economic productivity. The emergence of novel strains of influenza viruses presents a public health threat, with potential rapid global spread among people with no pre-existing immunity to the virus, causing catastrophic morbidity and mortality. The Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR), is launching a new initiative supporting the advanced development of influenza vaccine candidates with the goal to provide enhanced, long-lasting protection from a broad range of antigenically divergent influenza viruses within and across subtypes. These new vaccines will be more effective than current vaccines in providing protection from influenza infection in people of all ages and in people generally considered high-risk for severe disease associated with influenza infection. Additionally, these new vaccines may serve as a priming dose during non-pandemic periods to enable a single dose of a pandemic influenza vaccine to be effective. As such, promising experimental data providing evidence that the new vaccine may serve as a primer for a pandemic influenza vaccine booster will be evaluated favorably. Offerors are required to develop these vaccine candidates towards final FDA licensure for prophylaxis against disease caused by seasonal and pandemic influenza. HHS/ASPR/Acquisition Management, Contracts and Grants (AMCG) is publishing a Request for Proposals (RFP) to support the advanced development of new influenza vaccines that are more effective than currently licensed vaccines as a step towards development of a universal influenza vaccine with potential prime- boost vaccine properties for pandemic influenza. This RFP provides additional details regarding the desired characteristics for the development towards a universal influenza vaccine candidate through a defined target product profile (TPP). BARDA contemplates a single or multiple contract award(s) to develop, manufacture, and evaluate more effective influenza vaccine candidate(s) toward US licensure. Any responsible offeror may submit a proposal that will be considered by the Government. This notice does not commit the Government to the award of a contract. It is the Offeror's responsibility to monitor this website (www.fbo.gov) for the release of any subsequent amendments to the solicitation. Potential offerors will be responsible for downloading their own copy of the solicitation and any amendments via www.fbo.gov. All inquiries concerning this requirement must be identified with the RFP number, name of firm, name of requestor, mailing address, telephone number, email address and must be submitted to the primary and/or secondary point of contact identified in this notice.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/OOS/OASPHEP/BARDA_Universal_Influenza_Synopsis/listing.html)
- Record
- SN03668793-W 20150318/150316234821-6c7c066a375f3ea79b3f9848699cbabc (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |